Fear of Cancer Recurrence and Associated Factors in Lymphoma Survivors and Their Family Caregivers: A Cross-Sectional Study

IF 3.1 2区医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2025-03-29 DOI:10.1002/cam4.70561

Taha Koray Sahin, Ezgi Aysu Sahin, Hande Nur Gungor, Deniz Can Guven, Ibrahim Barista, Serkan Akin

{"title":"Fear of Cancer Recurrence and Associated Factors in Lymphoma Survivors and Their Family Caregivers: A Cross-Sectional Study","authors":"Taha Koray Sahin, Ezgi Aysu Sahin, Hande Nur Gungor, Deniz Can Guven, Ibrahim Barista, Serkan Akin","doi":"10.1002/cam4.70561","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Fear of cancer recurrence (FCR) is a pervasive concern among lymphoma survivors and their family caregivers, influencing psychological and physical health. Given the substantial burden of FCR, identifying its predictors is crucial for targeted interventions that could enhance palliative care. We aimed to evaluate the prevalence of FCR in lymphoma survivors and their caregivers, as well as associated factors</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A total of 118 patients with lymphoma, along with their family caregivers, were recruited from Hacettepe University Cancer Institute between March 2024 and May 2024. Psychological assessments were conducted using the Depression Anxiety Stress Scales (DASS-21), the Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF) and the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>High levels of FCR were experienced by 50.8% (<i>n</i> = 60) of lymphoma survivors and 57.6% (<i>n</i> = 68) of their caregivers. There was a positive correlation between the FCR of the survivors and caregivers (<i>r</i> = 0.349, <i>p</i> < 0.001). Poor overall quality of life (QoL) (aOR: 4.279, 95% CI: 1.738–10.531, <i>p</i> = 0.002), recent diagnosis (< 3 year) (aOR: 5.135, 95% CI: 1.852–14.238, <i>p</i> = 0.002), survivors' anxiety (aOR: 2.540, 95% CI: 1.014–6.363, <i>p</i> = 0.002) and caregivers' FCR (aOR: 2.970, 95% CI: 1.119–7.879, <i>p</i> = 0.029) were associated with high levels of FCR in lymphoma survivors.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>We observed high FCR levels in over half the survivors with lymphoma and a higher FCR risk in patients with anxiety, poor QoL and caregiver FCR. These findings highlight the critical need for developing comprehensive care plans and interventions targeting FCR in patients with lymphoma.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 7","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70561","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70561","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Fear of cancer recurrence (FCR) is a pervasive concern among lymphoma survivors and their family caregivers, influencing psychological and physical health. Given the substantial burden of FCR, identifying its predictors is crucial for targeted interventions that could enhance palliative care. We aimed to evaluate the prevalence of FCR in lymphoma survivors and their caregivers, as well as associated factors

Methods

A total of 118 patients with lymphoma, along with their family caregivers, were recruited from Hacettepe University Cancer Institute between March 2024 and May 2024. Psychological assessments were conducted using the Depression Anxiety Stress Scales (DASS-21), the Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF) and the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)

Results

High levels of FCR were experienced by 50.8% (n = 60) of lymphoma survivors and 57.6% (n = 68) of their caregivers. There was a positive correlation between the FCR of the survivors and caregivers (r = 0.349, p < 0.001). Poor overall quality of life (QoL) (aOR: 4.279, 95% CI: 1.738–10.531, p = 0.002), recent diagnosis (< 3 year) (aOR: 5.135, 95% CI: 1.852–14.238, p = 0.002), survivors' anxiety (aOR: 2.540, 95% CI: 1.014–6.363, p = 0.002) and caregivers' FCR (aOR: 2.970, 95% CI: 1.119–7.879, p = 0.029) were associated with high levels of FCR in lymphoma survivors.

Conclusion

We observed high FCR levels in over half the survivors with lymphoma and a higher FCR risk in patients with anxiety, poor QoL and caregiver FCR. These findings highlight the critical need for developing comprehensive care plans and interventions targeting FCR in patients with lymphoma.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

淋巴瘤幸存者及其家庭照顾者对癌症复发的恐惧及其相关因素：一项横断面研究

癌症复发恐惧（FCR）是淋巴瘤幸存者及其家庭照顾者普遍关注的问题，影响着心理和身体健康。鉴于FCR的巨大负担，确定其预测因素对于有针对性的干预措施至关重要，可以加强姑息治疗。我们的目的是评估FCR在淋巴瘤幸存者及其照顾者中的患病率，以及相关因素。方法在2024年3月至2024年5月期间，从Hacettepe大学癌症研究所招募了118名淋巴瘤患者及其家庭照顾者。采用抑郁焦虑压力量表（DASS-21）、癌症复发恐惧量表-短表（FCRI-SF）和癌症治疗-淋巴瘤功能评估（FACT-Lym）进行心理评估。结果50.8% （n = 60）的淋巴瘤幸存者和57.6% （n = 68）的照顾者经历了高水平的FCR。幸存者的FCR与照顾者之间存在正相关（r = 0.349, p < 0.001）。总体生活质量差（QoL）（aOR: 4.279, 95% CI: 1.738-10.531, p = 0.002）、近期诊断（<； 3年）（aOR: 5.135, 95% CI: 1.852-14.238, p = 0.002）、幸存者焦虑（aOR: 2.540, 95% CI: 1.014-6.363, p = 0.002）和护理者的FCR （aOR: 2.970, 95% CI: 1.119-7.879, p = 0.029）与淋巴瘤幸存者高水平的FCR相关。结论：我们观察到超过一半的淋巴瘤幸存者的FCR水平较高，焦虑、生活质量差和照顾者FCR患者的FCR风险较高。这些发现强调了制定针对淋巴瘤患者FCR的综合护理计划和干预措施的迫切需要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.